The mechanism of action of mesalamine is not fully understood, but appears to be topical rather than systemic. Although the pathology of inflammatory bowel disease is uncertain, both prostaglandins and leukotrienes have been implicated as mediators of mucosal injury and inflammation.

CANASA is a reaction is suspected. (5.3) n aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis.

The recommended adult dosage is 1000 mg administered rectally once daily at alternative, selective assay for normetanephrine. bedtime for 3 to 6 weeks. Safety and effectiveness beyond 6 weeks have not been established.

The most common adverse reactions (≥ 1%) are: dizziness, rectal pain, fever, rash, acne and colitis.

Known or suspected hypersensitivity to salicylates or aminosalicylates or to any or to any ingredients in the formulation.

•Renal Impairment: Evaluate the risks and benefits in patients with known renal impairment or taking nephrotoxic drugs; monitor renal function. •Mesalamine-Induced Acute Intolerance Syndrome: Symptoms may be difficult to distinguish from an exacerbation of ulcerative colitis; monitor for worsening symptoms; discontinue treatment if acute intolerance syndrome is suspected. •Hypersensitivity Reactions, including Myocarditis and Pericarditis: Evaluate patients immediately and discontinue if a hypersensitivity reaction is suspected. •Hepatic Failure: Evaluate the risks and benefits in patients with known liver impairment. •Interaction with Laboratory Test for Urinary Normetanephrine: Spuriously elevated test results may occur with liquid chromatography with electrochemical detection in patients receiving CANASA; use alternative, selective assay for normetanephrine.